Advertisement

Digestive Diseases and Sciences

, Volume 39, Issue 8, pp 1638–1641 | Cite as

Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity

  • Charles N. Bernstein
  • Lucy Artinian
  • Peter A. Anton
  • Fergus Shanahan
Original Articles

Abstract

A feared complication of therapy with 6-mercaptopurine (6-MP) is myelosuppression. To evaluate whether rigorous blood count monitoring is necessary, we prospectively followed the hematologic profiles of 57 patients with inflammatory bowel disease who were treated with low-dose 6-MP. Most patients (97%) were treated initially with a single dose of 50 mg/day and 79% never used more than 50 mg/day. Blood counts were obtained at weekly intervals over the first month, every two weeks for the second month, and monthly thereafter in the first year. Sixteen (28%) developed mild leukopenia (white blood count <4.5×103/mm3). No patient had a white blood cell count <2.8×103/mm3 and no patient developed leukopenia prior to three months of treatment. In only five patients did the leukopenia prompt a change in 6-mercaptopurine dose. Very mild thrombocytopenia (platelet count of <145×103/mm3) developed in three (5%) and macrocytosis (mean cell volume >101 fl) was seen in nine (16%). In conclusion, leukopenia was not uncommon in patients treated with low-dose 6-MP, but was not clinically significant. Leukopenia occurred no earlier than three months and as late as 42 months into therapy. Thrombocytopenia was uncommon, mild, and was not associated with apparent bleeding. Macrocytosis may occur in the absence of vitamin B12 and folate deficiencies. Patients can be spared from weekly blood count monitoring when using low-dose 6-mercaptopurine treatment.

Key words

6-mercaptopurine purine analogs inflammatory bowel disease leukopenia thrombocytopenia macrocytosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bernstein CN, Shanahan F: Immunosuppressive and immunomodulatory therapy for inflammatory bowel disease. Can J Gastroenterol 7:115–120, 1993Google Scholar
  2. 2.
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS: Treatment of Crohn's disease with 6-mercaptopurine. A long term randomized double blind study. N Engl J Med 302:981–987, 1980Google Scholar
  3. 3.
    Hawthorne AB, Logan RFA, Hawkey CJ, Forster PN, Axon ATR, Swarbrick ET, Scott BB, Lennard-Jones JE: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 305:20–22, 1992Google Scholar
  4. 4.
    Markowitz J, Grancher K, Mandel F, Daum F, for the Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum: Immunosuppressive therapy in pediatric inflammatory bowel disease: Results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Am J Gastroenterol 88:44–48, 1993Google Scholar
  5. 5.
    Rhodes J, Bainton D, Beck P, Campbell H: Controlled trial of azathioprine in Crohn's disease. Lancet 2:1273–1276, 1971Google Scholar
  6. 6.
    Present DH: 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am 18:57–71, 1989Google Scholar
  7. 7.
    Younger IR, Harris DWS, Colver GB: Azathioprine in dermatology. J Am Acad Dermatol 25:281–286, 1991Google Scholar
  8. 8.
    Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI: 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 111:641–649, 1989Google Scholar
  9. 9.
    Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34:1081–1085, 1993Google Scholar
  10. 10.
    Chan GLC, Canafax DM, Johnson CA: The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 7:165–177, 1987Google Scholar
  11. 11.
    Lennard L, Van Loon JSA, Lilleyman JS, Weinshilboum RM: Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41:18–25, 1987Google Scholar
  12. 12.
    Van Loon J, Weinshilboum RM: Thiopurine methyltransferase biochemical genetics human lymphocyte activity. Biochem Genet 20:637–658, 1982Google Scholar
  13. 13.
    Sandborn WJ, Tremane WJ: Measurement of thiopurine methyltransferase (TMPT) activity in patients with inflammatory bowel disease (IBD) does not predict side effects from treatment with 6-mercatopurine (6-MP) or azathioprine. Gastroenterology 104:A774, 1993Google Scholar
  14. 14.
    Wickramasinghe SN, Dodsworth H, Rault RMJ, Hulme B: Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation 18:443–446, 1974Google Scholar
  15. 15.
    Lennard L, Murphy MF, Maddocks JL: Severe megaloblastic anemia associated with abnormal azathioprine metabolism. Br J Clin Pharmacol 17:171–172, 1984Google Scholar
  16. 16.
    Roman J, Westervelt F, Atuk N, Wheby M: The occurrence of megaloblastic anemia with normal serum folate during antipurine therapy. Clin Res 21:94, 1973Google Scholar
  17. 17.
    Kuks JBM, Djojoatmodjo S, Oosterhuis HJHG: Azathioprine in myasthenia gravis: Observations in 41 patients and a review of literature. Neuromusc Dis 1:423–431, 1991Google Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • Charles N. Bernstein
    • 1
  • Lucy Artinian
    • 1
  • Peter A. Anton
    • 1
  • Fergus Shanahan
    • 1
  1. 1.From the Department of MedicineUniversity of CaliforniaLos Angeles

Personalised recommendations